Table 3 Single factor analysis.
Description | OR | p Value (Z) | |
---|---|---|---|
Age at first clinic visit (y) | 1.00 | 0.64 | |
Duration of psoriasis at clinic entry (y) | 0.99 | 0.14 | |
Duration of psoriatic arthritis at clinic entry (years) | 0.98 | 0.035 | |
Family history of psoriasis (yes/no) | 0.82 | 0.25 | |
Family history of psoriatic arthritis (yes/no) | 1.30 | 0.39 | |
ESR at clinic entry (abnormal/normal) | 0.80 | 0.27 | |
Rheumatoid factor at clinic entry (present/absent) | 1.12 | 0.66 | |
Drug treatment | |||
NSAIDs | 1 | 0.66* | |
DMARDs | 0.90 | ||
IAS | 0.67 | ||
None | 0.84 | ||
Antinuclear antibody (present/absent) | 0.85 | 0.41 | |
Age at onset of psoriasis (y) | 1.00 | 0.43 | |
Age at onset of arthritis (y) | 1.01 | 0.34 | |
History of activity before damage (present/absent) | 0.92 | 0.50 | |
History of effusion before damage (present/absent) | 1.12 | 0.43 | |
Recent history of effusion (present/absent) | 1.73 | 0.002 | |
Current effused joint (yes/no) | 1.24 | 0.16 | |
Duration of psoriasis at time of damage (y) | 0.99 | 0.03 | |
Duration of psoriatic arthritis at time of damage (y) | 0.98 | 0.01 | |
ESR at time of damage (abnormal/normal) | 0.88 | 0.55 |
*Likelihood ratio test.
ESR, erythrocyte sedimentation rate; IAS, intra‐articular steroids; DMARD, disease modifying antirheumatic drug; NSAID, non‐steroidal anti‐inflammatory drug; OR, odds ratio; y, years.